Business Overview
Company Profile
Allient (formerly Allied Motion Technologies) designs and manufactures precision motion technology products for high-demand applications in defense, medical, industrial automation, and commercial vehicles. The company rebranded to Allient in 2023, reflecting its evolved identity as a diversified motion solutions provider.
End Markets:
Defense & Aerospace (~30%) Medical (~20%) Industrial Automation (~25%) Commercial Vehicles (~15%) Other (~10%)
Products include brushless DC motors, servo drives, encoders, gearboxes, and integrated motion systems. Allient's components are found in surgical robots, military targeting systems, EV drivetrains, and autonomous vehicles.
End Markets:
Defense & Aerospace (~30%) Medical (~20%) Industrial Automation (~25%) Commercial Vehicles (~15%) Other (~10%)
Products include brushless DC motors, servo drives, encoders, gearboxes, and integrated motion systems. Allient's components are found in surgical robots, military targeting systems, EV drivetrains, and autonomous vehicles.
Investment Thesis
1. Defense pivot: Management accelerating shift toward defense and aerospace end markets — higher margin, longer-cycle, and contractually protected revenues. Defense now ~30% of revenue and growing.
2. Medical robotics expansion: Surgical robot actuators (da Vinci-type systems) require Allient's precision motors. Medical robotics market growing 15%+ annually drives high-ASP orders.
3. Margin recovery: FY2025 EBITDA margins rebounded to 13.2% from 10.6% (FY2024 trough) — trend toward 15%+ as defense and medical mix increases.
4. Perfect SmartScore 10: Despite stock trading above analyst consensus PT, the composite score reflects strong fundamentals, insider buying, hedge fund accumulation.
5. EV/Automation exposure: EV drivetrain and industrial robot actuator demand creates a secular growth tailwind beyond traditional industrial cycles.
2. Medical robotics expansion: Surgical robot actuators (da Vinci-type systems) require Allient's precision motors. Medical robotics market growing 15%+ annually drives high-ASP orders.
3. Margin recovery: FY2025 EBITDA margins rebounded to 13.2% from 10.6% (FY2024 trough) — trend toward 15%+ as defense and medical mix increases.
4. Perfect SmartScore 10: Despite stock trading above analyst consensus PT, the composite score reflects strong fundamentals, insider buying, hedge fund accumulation.
5. EV/Automation exposure: EV drivetrain and industrial robot actuator demand creates a secular growth tailwind beyond traditional industrial cycles.
Financial Summary (FY ends December)
| Metric | FY2021A | FY2022A | FY2023A | FY2024A | FY2025A | FY2026E | FY2027E |
|---|---|---|---|---|---|---|---|
| Revenue ($M) | $403 | $503 | $579 | $530 | $554 | $620 | $700 |
| Gross Margin | 30.0% | 31.3% | 31.7% | 31.3% | 30.5% | 32.0% | 33.5% |
| Op. Margin | 6.5% | 6.3% | 7.3% | 5.7% | 8.7% | 10.0% | 11.5% |
| EBITDA Margin | 11.0% | 11.3% | 11.6% | 10.6% | 13.2% | 14.5% | 15.5% |
| Net Income ($M) | $24.1 | $17.4 | $24.1 | $13.2 | $22.0 | $35 | $50 |
| EPS (Diluted) | $1.66 | $1.09 | $1.48 | $0.79 | $1.32 | $2.10 | $3.00 |
| FCF ($M) | $11.7 | -$10.3 | $33.4 | $32.2 | $49.7 | $60 | $75 |
| Net Debt ($M) | $153.8 | $228.2 | $211.6 | $213.0 | $156.1 | $100 | $40 |
| D/E Ratio | 0.94 | 1.20 | 0.97 | 0.94 | 0.65 | 0.45 | 0.25 |
* FY2024 revenue dip reflects commercial vehicle softness; FY2025 recovery driven by defense and medical. FY2026-27E reflect defense mix ramp.
12-Month Price History
Revenue & EPS Trend (FY2021–FY2027E)
Peer Comparison — Small-Cap Precision Motion
| Company | Ticker | Mkt Cap | P/E | EBITDA Mgn | Rev Growth | SmartScore | Rating |
|---|---|---|---|---|---|---|---|
| Allient Inc. | ALNT | $1.35B | 55.5× | 13.2% | +4.6% | 10 | Strong Buy |
| Moog Inc. | MOG.A | $11.4B | 40.1× | 12.7% | +7.0% | 7 | Buy |
| Maxon Group | Private | — | — | — | — | — | — |
| Haynes International | HAYN | ~$0.8B | ~20× | ~18% | +2% | — | Hold |
| NN Group | NNBR | ~$0.5B | — | ~10% | -2% | — | Hold |
ALNT is a small-cap with limited direct comparables. The 55× P/E reflects the market pricing in a significant earnings recovery to $2.50-$3.00 by FY2027.
Price Target Scenarios
🚀 Bull Case
$110
+39% upside
Defense and medical robotics drive revenue to $700M+ by FY2027. EBITDA margins reach 16%. EPS recovers to $3.50+. 30× on $3.50E with small-cap premium for high-growth profile. Potential M&A target for larger defense/aerospace consolidator.
📊 Base Case
$85
+7% upside
Revenue reaches $620-700M by FY2027 with 14-15% EBITDA margins. EPS of $2.10-$3.00 by FY2027. ~28-30× on $3.00E EPS. Defense and medical mix shift supports premium valuation. Debt reduction continues.
⚠️ Bear Case
$45
-43% downside
Commercial vehicle end market continues weak; defense ramp slower than expected; medical robotics OEM delays. EPS stays below $1.50 through FY2027. Multiple contracts to 25-30× on limited earnings recovery. Stock significantly above analyst PT a risk.
Key Catalysts
Q2 2026 Earnings (Aug 5, 2026)
Defense segment bookings and medical robotics order update critical. EPS recovery trajectory toward $2+ is the key narrative investors will be watching.
Medical Robotics Wins
New surgical robot OEM customer wins (da Vinci, CMR, Medtronic Hugo) represent multi-year volume commitments with high ASPs. Any public win announcement is a major catalyst.
Defense Program Awards
Unmanned vehicle (UGV/UAV) actuation systems and guided munitions components represent high-value, long-cycle defense contracts. Awards drive backlog and earnings visibility.
Industrial Automation Recovery
Robotics and automation capex cycle recovery in North America and Europe would reaccelerate industrial segment revenue which has been under pressure since 2023.
Key Risks
Stock Above Analyst PT
At $79, ALNT trades 7% above the $73.80 consensus analyst target. Any EPS miss at this elevated multiple (55×) could cause significant drawdown as sentiment reverses.
Commercial Vehicle Weakness
Commercial vehicle end market remains under pressure from higher rates impacting fleet financing. CV represents ~15% of revenue and has been a drag on growth since FY2023.
EPS Recovery Path Risk
FY2025 EPS of $1.32 is still far below the peak of $1.66 (FY2021). The 55× P/E is pricing in significant earnings acceleration — any delay extends the payback period.
Small-Cap Liquidity
$1.35B market cap with limited analyst coverage creates liquidity risk. Small institutional positions can cause outsized price moves on news. Bid-ask spreads can be wide.
Technical Analysis
Summary Signal
OverallBuy (15B/2N/5S)
Moving AveragesStrong Buy (12B/0S)
OscillatorsSell (overbought)
RSI (14)67.6 — Elevated
Stochastic94.8 — Overbought
ADX (14)26.2 — Moderate trend
ATR (14)$4.16 / day
Key Levels
Current Price$79.16
5-Day MA$72.78 (support)
50-Day MA$67.85 (strong support)
200-Day MA$57.78 (deep support)
Resistance R1$76.72
Resistance R2$78.85
52W High$80 (near ATH)
⚡ Technical Note: ALNT is up 160% in 12 months testing 52W highs near $80. Stochastics at 94.8 signal overbought near-term. All 12 MAs signal Buy with price well above all averages. Short-term consolidation likely — potential retracement to $67-72 (50-day MA) on any earnings disappointment. Long-term bull trend firmly intact.
Market Sentiment
Analyst Consensus
Strong Buy
4 Buy / 1 Hold / 0 Sell
Avg Price Target
$73.80
Stock trading above PT
Hedge Fund Score
0.68 — Buy
Institutional accumulation
SmartScore
10 / 10
Perfect composite
1-Year Return
+160.4%
Best performer in coverage
Insider Activity
Buying
Recent insider purchases
Coverage
5 analysts
Growing research interest
Next Earnings
Aug 5, 2026
Q2 2026
📊 Bottom Line
Allient is the highest-momentum small-cap in our coverage — up 160% in 12 months with a perfect SmartScore of 10. The defense pivot and medical robotics exposure create a genuine multi-year earnings recovery story: EPS from $1.32 (FY2025) toward $3.00+ (FY2027E). The SmartScore 10 despite trading above the $73.80 analyst consensus suggests institutional buyers disagree with the sell-side consensus and see higher earnings potential. High-risk/high-reward: at 55× current earnings, any earnings miss triggers severe drawdown, but the defense and robotics tailwinds are real. Price Target: $85 (+7%). Rating: Strong Buy — position-size carefully given small-cap volatility. Best for risk-tolerant investors.